Format

Send to

Choose Destination
J Hematol Oncol. 2018 Jan 16;11(1):10. doi: 10.1186/s13045-017-0549-1.

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel.

Author information

1
Department of Hematology, CHU de Liège, Liège, Belgium. jo.caers@chu.ulg.ac.be.
2
Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicadas (CIMA); Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBERONC, Pamplona, Spain.
3
Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
4
Hopital La Miletrie, University Hospital of Poitiers, Poitiers, France.
5
Department of Hematology, Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain.
6
Department of Hematology, Landspitali National University Hospital, Reykjavik, Iceland.
7
Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France.
8
Department of Hematology, Odense University Hospital, Odense, Denmark.
9
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
10
Department of Hematology, CHU de Liège, Liège, Belgium.
11
Instituto de Investigacion Biomedica de Salamanca, Centro de Investigación del Cancer, Hospital Universitario de Salamanca, Salamanca, Spain.
12
Department of Hematology, University Hospital Leuven, Leuven, Belgium.
13
Department of Haematology, Oncology, and Bone Marrow Transplantation, Universitaetsklinikum Eppendorf, Hamburg, Germany.
14
Department of Hematology, University of Ankara, Ankara, Turkey.
15
Department of Medicine I, Wilhelminen Hospital, Vienna, Austria.
16
Department of Molecular Medicine, Amyloidosis Research and Treatment Center, Foundation 'Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo', University of Pavia, Pavia, Italy.
17
Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands.
18
Department of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany.

Abstract

Solitary plasmacytoma is an infrequent form of plasma cell dyscrasia that presents as a single mass of monoclonal plasma cells, located either extramedullary or intraosseous. In some patients, a bone marrow aspiration can detect a low monoclonal plasma cell infiltration which indicates a high risk of early progression to an overt myeloma disease. Before treatment initiation, whole body positron emission tomography-computed tomography or magnetic resonance imaging should be performed to exclude the presence of additional malignant lesions. For decades, treatment has been based on high-dose radiation, but studies exploring the potential benefit of systemic therapies for high-risk patients are urgently needed. In this review, a panel of expert European hematologists updates the recommendations on the diagnosis and management of patients with solitary plasmacytoma.

KEYWORDS:

Extramedullary plasmacytoma; MRI; Myeloma; PET/CT; Plasma cell dyscrasia; Radiotherapy; Solitary plasmacytoma

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center